Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
Department of Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.
Front Immunol. 2023 May 25;14:1203929. doi: 10.3389/fimmu.2023.1203929. eCollection 2023.
Type I interferons have long been appreciated as a cytokine family that regulates antiviral immunity. Recently, their role in eliciting antitumor immune responses has gained increasing attention. Within the immunosuppressive tumor microenvironment (TME), interferons stimulate tumor-infiltrating lymphocytes to promote immune clearance and essentially reshape a "cold" TME into an immune-activating "hot" TME. In this review, we focus on gliomas, with an emphasis on malignant glioblastoma, as these brain tumors possess a highly invasive and heterogenous brain TME. We address how type I interferons regulate antitumor immune responses against malignant gliomas and reshape the overall immune landscape of the brain TME. Furthermore, we discuss how these findings can translate into future immunotherapies targeting brain tumors in general.
I 型干扰素长期以来一直被认为是一种细胞因子家族,可调节抗病毒免疫。最近,它们在引发抗肿瘤免疫反应方面的作用引起了越来越多的关注。在免疫抑制性肿瘤微环境 (TME) 中,干扰素刺激肿瘤浸润淋巴细胞以促进免疫清除,并从本质上将“冷”TME 重塑为免疫激活的“热”TME。在这篇综述中,我们重点关注神经胶质瘤,特别是恶性神经胶质瘤,因为这些脑肿瘤具有高度侵袭性和异质性的脑 TME。我们讨论了 I 型干扰素如何调节针对恶性神经胶质瘤的抗肿瘤免疫反应,并重塑脑 TME 的整体免疫景观。此外,我们还讨论了这些发现如何转化为针对一般脑肿瘤的未来免疫疗法。